Table 1 Patients’ baseline characteristics
Male/female | 4/5 |
Age(y) | 73.6 ± 6.2 |
Dialysis vintage(y) | 11 (7–19) |
Primary disease | DM:3/CGN:5/PCK:1 |
Hb(g/dL) | 10.4 ± 0.6 |
Ret (104/mL) | 2.1 ± 0.8 |
TSAT(%) | 38.4 ± 11.9 |
CHr (pg) | 33.6 ± 1.0 |
FRN (ng/mL) | 98.9 (63.4–122.7) |
HEPC (ng/mL) | 0.5 ± 0.3 |
ERFE (ng/mL) | 1.4 ± 0.8 |
iFGF23 (pg/mL) | 665 (164–879) |
cFGF23 (pg/mL) | 115 (62–198) |
hsCRP (ng/dL) | 0.11 (0.06–1.05) |
IL-6 (pg/dL) | 17.2 ± 22.9 |
Alb(g/dL) | 3.5 ± 0.2 |
CCa (mg/dL) | 8.8 ± 0.4 |
IP (mg/dL) | 5.1 ± 0.8 |
Whole PTH (pg/dL) | 94.6 (68.9–150) |
CERA dosage at weeks 0 and 4(μg/4 W) | 109 ± 39 |